EP2715352A4 - Procédé d'évaluation du risque de lemp - Google Patents

Procédé d'évaluation du risque de lemp

Info

Publication number
EP2715352A4
EP2715352A4 EP12792375.3A EP12792375A EP2715352A4 EP 2715352 A4 EP2715352 A4 EP 2715352A4 EP 12792375 A EP12792375 A EP 12792375A EP 2715352 A4 EP2715352 A4 EP 2715352A4
Authority
EP
European Patent Office
Prior art keywords
pml
assessing risk
assessing
risk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP12792375.3A
Other languages
German (de)
English (en)
Other versions
EP2715352A2 (fr
EP2715352B1 (fr
Inventor
Meena Subramanyam
Tatiana Plavina
Gary Lewis Bloomgren
Carmen Bozic
Sophia Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47260338&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP2715352(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to EP22209669.5A priority Critical patent/EP4187248A1/fr
Priority to DK19169482.7T priority patent/DK3575792T3/da
Priority to PL12792375T priority patent/PL2715352T3/pl
Priority to SI201231596T priority patent/SI2715352T1/sl
Application filed by Biogen MA Inc filed Critical Biogen MA Inc
Priority to RS20190690A priority patent/RS58967B1/sr
Priority to EP19169482.7A priority patent/EP3575792B1/fr
Publication of EP2715352A2 publication Critical patent/EP2715352A2/fr
Publication of EP2715352A4 publication Critical patent/EP2715352A4/fr
Publication of EP2715352B1 publication Critical patent/EP2715352B1/fr
Application granted granted Critical
Priority to HRP20190860TT priority patent/HRP20190860T1/hr
Revoked legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Exhaust Gas After Treatment (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
EP12792375.3A 2011-05-31 2012-05-31 Procédé d'évaluation du risque de lemp Revoked EP2715352B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP19169482.7A EP3575792B1 (fr) 2011-05-31 2012-05-31 Procédé d'évaluation du risque de lemp
DK19169482.7T DK3575792T3 (da) 2011-05-31 2012-05-31 Fremgangsmåde til vurdering af risiko for pml
PL12792375T PL2715352T3 (pl) 2011-05-31 2012-05-31 Metoda oceny ryzyka postępującej wieloogniskowej leukoencefalopatii (pml)
SI201231596T SI2715352T1 (sl) 2011-05-31 2012-05-31 Metoda ocenjevanja tveganja za nastanek PML
EP22209669.5A EP4187248A1 (fr) 2011-05-31 2012-05-31 Procédé d'évaluation du risque de lemp
RS20190690A RS58967B1 (sr) 2011-05-31 2012-05-31 Metod evaluacije rizika za pml
HRP20190860TT HRP20190860T1 (hr) 2011-05-31 2019-05-09 POSTUPAK PROCJENJIVANJA RIZIKA OD PML-a

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161491810P 2011-05-31 2011-05-31
US201161508584P 2011-07-15 2011-07-15
US201161550257P 2011-10-21 2011-10-21
US201261636588P 2012-04-20 2012-04-20
PCT/US2012/040283 WO2012166971A2 (fr) 2011-05-31 2012-05-31 Procédé d'évaluation du risque de lemp

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP19169482.7A Division EP3575792B1 (fr) 2011-05-31 2012-05-31 Procédé d'évaluation du risque de lemp
EP22209669.5A Division EP4187248A1 (fr) 2011-05-31 2012-05-31 Procédé d'évaluation du risque de lemp

Publications (3)

Publication Number Publication Date
EP2715352A2 EP2715352A2 (fr) 2014-04-09
EP2715352A4 true EP2715352A4 (fr) 2015-10-21
EP2715352B1 EP2715352B1 (fr) 2019-04-24

Family

ID=47260338

Family Applications (3)

Application Number Title Priority Date Filing Date
EP19169482.7A Active EP3575792B1 (fr) 2011-05-31 2012-05-31 Procédé d'évaluation du risque de lemp
EP12792375.3A Revoked EP2715352B1 (fr) 2011-05-31 2012-05-31 Procédé d'évaluation du risque de lemp
EP22209669.5A Pending EP4187248A1 (fr) 2011-05-31 2012-05-31 Procédé d'évaluation du risque de lemp

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP19169482.7A Active EP3575792B1 (fr) 2011-05-31 2012-05-31 Procédé d'évaluation du risque de lemp

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP22209669.5A Pending EP4187248A1 (fr) 2011-05-31 2012-05-31 Procédé d'évaluation du risque de lemp

Country Status (19)

Country Link
US (2) US12105090B2 (fr)
EP (3) EP3575792B1 (fr)
JP (5) JP6243838B2 (fr)
KR (3) KR102292563B1 (fr)
CN (1) CN103635803A (fr)
AU (1) AU2012262122B2 (fr)
CA (1) CA2836490A1 (fr)
CY (1) CY1121981T1 (fr)
DK (2) DK2715352T3 (fr)
ES (2) ES2729945T3 (fr)
FI (1) FI3575792T3 (fr)
HR (2) HRP20230186T1 (fr)
HU (2) HUE043339T2 (fr)
LT (2) LT2715352T (fr)
PL (2) PL3575792T3 (fr)
PT (2) PT2715352T (fr)
RS (2) RS63989B1 (fr)
SI (2) SI3575792T1 (fr)
WO (1) WO2012166971A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2676967T (lt) 2006-02-28 2019-09-10 Biogen Ma Inc. Uždegiminių ir autoimuninių ligų gydymo būdai su natalizumabu
ES2663377T3 (es) 2006-03-03 2018-04-12 Biogen Ma Inc. Métodos para el tratamiento de enfermedades inflamatorias y autoinmunes con natalizumab
AU2010303156B2 (en) 2009-10-11 2016-02-04 Biogen Ma Inc. Anti-VLA-4 related assays
BR112012017014B1 (pt) 2010-01-11 2021-07-20 Biogen Ma Inc Métodos para detecção de anticorpos de vírus jc
US11287423B2 (en) 2010-01-11 2022-03-29 Biogen Ma Inc. Assay for JC virus antibodies
HUE043339T2 (hu) 2011-05-31 2019-08-28 Biogen Ma Inc Módszer a PML kockázatának megállapítására
WO2014193804A1 (fr) 2013-05-28 2014-12-04 Biogen Idec Ma Inc. Méthodes d'évaluation de risque de développement d'une lemp
US20160223565A1 (en) * 2013-09-18 2016-08-04 The Johns Hopkins University Bk virus serology assessment of progressive multifocal leukoencephalopathy (pml) risk
ES2818823T3 (es) * 2014-02-27 2021-04-14 Biogen Ma Inc Método de evaluación del riesgo de LMP
MA40985A (fr) 2014-11-17 2017-09-26 Biogen Ma Inc Méthodes de traitement de la sclérose en plaques
KR20200088350A (ko) 2017-10-26 2020-07-22 바이오젠 엠에이 인코포레이티드 나탈리주맙의 시간간격이 길어진 투약법
EP4243932A1 (fr) 2020-11-14 2023-09-20 Biogen MA Inc. Schémas posologiques sous-cutanés biphasiques pour des anticorps anti-vla-4
WO2022221458A1 (fr) 2021-04-13 2022-10-20 Biogen Ma Inc Compositions et méthodes de traitement de lésions chroniques actives de la matière blanche/syndrome radiologiquement isolé

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011085369A1 (fr) * 2010-01-11 2011-07-14 Biogen Idec Ma Inc. Essai d'anticorps anti-virus jc

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4235601A (en) 1979-01-12 1980-11-25 Thyroid Diagnostics, Inc. Test device and method for its use
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
US4703017C1 (en) 1984-02-14 2001-12-04 Becton Dickinson Co Solid phase assay with visual readout
NZ215865A (en) 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
CA1291031C (fr) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Methode pour la detection de liants specifiques et des substances liables par ceux-ci
US5763262A (en) 1986-09-18 1998-06-09 Quidel Corporation Immunodiagnostic device
DE291194T1 (de) 1987-04-27 1992-03-19 Unilever N.V., Rotterdam Immunoassays und vorrichtungen dafuer.
US4943522A (en) 1987-06-01 1990-07-24 Quidel Lateral flow, non-bibulous membrane assay protocols
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
US4818677A (en) 1987-12-03 1989-04-04 Monoclonal Antibodies, Inc. Membrane assay using focused sample application
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US5221616A (en) 1988-07-15 1993-06-22 Quidel Corporation Prevention of spontaneous complement activation in mammalian biological fluids
US5118630A (en) 1988-11-04 1992-06-02 Quidel Corporation Method for determining periodic infertility in females
US6352862B1 (en) 1989-02-17 2002-03-05 Unilever Patent Holdings B.V. Analytical test device for imuno assays and methods of using same
US6033665A (en) 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
US5084828A (en) 1989-09-29 1992-01-28 Healthtech Services Corp. Interactive medication delivery system
US5252496A (en) 1989-12-18 1993-10-12 Princeton Biomeditech Corporation Carbon black immunochemical label
US5096837A (en) 1990-02-08 1992-03-17 Pacific Biotech, Inc. Immunochromatographic assay and method of using same
US5223220A (en) 1990-03-27 1993-06-29 Pacific Biotech, Inc. Solid phase immunoassay device and method of making same
US5118428A (en) 1990-11-13 1992-06-02 Quidel Method to remove red blood cells from whole blood samples
DE4139840B4 (de) 1990-12-04 2005-06-02 Quidel Corp., San Diego Antigen-Zubereitung zum Nachweis von H. pylori
EP0566695B1 (fr) 1991-01-11 1999-06-02 Quidel Corporation Methode de dosage en une seule phase a flux lateral et support non- spongieux utilise dedans
US5213796A (en) 1991-05-06 1993-05-25 Dana Farber Cancer Institute Assay for polyomavirus in humans and uses thereof
US5225328A (en) 1991-05-30 1993-07-06 Quidel Corporation Stable alkaline phosphatase compositions with color enhancement and their use in assays
US5686315A (en) 1991-06-14 1997-11-11 Quidel Corporation Assay device for one step detection of analyte
EP0646179A4 (fr) 1992-02-04 1996-10-02 Quidel Corp Procede d'extraction simplifie d'antigenes bacteriens au moyen de reactifs deshydrates.
US5541069A (en) 1992-02-28 1996-07-30 Quidel Corporation Assay having improved dose response curve
JP2948318B2 (ja) 1992-03-10 1999-09-13 クイデル コーポレイション 特異的結合アッセイ用の赤血球の分離方法
DK0678122T3 (da) 1993-01-12 2000-03-06 Biogen Inc Rekombinante anti-VLA4 antistofmolekyler
US5415994A (en) 1993-08-02 1995-05-16 Quidel Corporation Lateral flow medical diagnostic assay device with sample extraction means
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5434057A (en) 1994-02-02 1995-07-18 Quidel Corporation Sperm motility assay and devices
US5521102A (en) 1994-08-08 1996-05-28 Quidel Corporation Controlled sensitivity immunochromatographic assay
US5845255A (en) 1994-10-28 1998-12-01 Advanced Health Med-E-Systems Corporation Prescription management system
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US5712172A (en) 1995-05-18 1998-01-27 Wyntek Diagnostics, Inc. One step immunochromatographic device and method of use
US5804452A (en) 1995-04-27 1998-09-08 Quidel Corporation One step urine creatinine assays
US5786220A (en) 1995-04-28 1998-07-28 Quidel Corporation Assays and devices for distinguishing between normal and abnormal pregnancy
US20010051350A1 (en) 1995-05-02 2001-12-13 Albert Nazareth Diagnostic detection device and method
US5773234A (en) 1995-08-07 1998-06-30 Quidel Corporation Method and device for chlamydia detection
DE19543553B4 (de) 1995-11-22 2009-04-09 Deutsches Primatenzentrum Gmbh VP-Antigene des JC-Virus
CN103275221B (zh) 1996-02-09 2016-08-17 艾伯维生物技术有限公司 结合人TNFα的人抗体
US6305377B1 (en) 1996-12-12 2001-10-23 Michael T. Portwood System and method for improving compliance of a medical regimen
US6229011B1 (en) 1997-08-22 2001-05-08 Hoffman-La Roche Inc. N-aroylphenylalanine derivative VCAM-1 inhibitors
US6306642B1 (en) 1997-11-24 2001-10-23 Quidel Corporation Enzyme substrate delivery and product registration in one step enzyme immunoassays
US6623981B2 (en) 1998-01-27 2003-09-23 Bristol-Myers Squibb Company Detection of patients at risk for developing integrin antagonist/agonist mediated disease states
US6014631A (en) 1998-04-02 2000-01-11 Merck-Medco Managed Care, Llc Computer implemented patient medication review system and process for the managed care, health care and/or pharmacy industry
US6045501A (en) 1998-08-28 2000-04-04 Celgene Corporation Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
US6407066B1 (en) 1999-01-26 2002-06-18 Elan Pharmaceuticals, Inc. Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4
US7171371B2 (en) 1999-09-03 2007-01-30 Smg Trust Method and system for providing pre and post operative support and care
AU7787100A (en) 1999-10-12 2001-04-23 Connex Gesellschaft Zur Optimierung Von Forschung Und Entwicklung Mbh Improved method for the detection of acid resistant microorganisms in a stool
US6388084B1 (en) 1999-12-06 2002-05-14 Hoffmann-La Roche Inc. 4-pyridinyl-n-acyl-l-phenylalanines
DE60043308D1 (de) 1999-12-16 2009-12-24 Biogen Idec Inc Verfahren zur behandlung der schädigung des zentralnervensystems durch ischämie oder durch hämorrhagie mit antagonisten von alpha4 integrin
AU2001233034A1 (en) 2000-01-27 2001-08-07 American Cyanamid Company Method for preparing alpha-sulfonyl hydroxamic acid derivatives
AU4465001A (en) 2000-03-30 2001-10-15 Nippon Kayaku Kabushiki Kaisha Method of examining cancer by assaying autoantibody against mdm2 and reagent therefor
US6620626B1 (en) 2000-08-09 2003-09-16 Mission Research Corp. Antigen detection device and method
MY129000A (en) 2000-08-31 2007-03-30 Tanabe Seiyaku Co INHIBITORS OF a4 MEDIATED CELL ADHESION
ATE403153T1 (de) 2000-10-17 2008-08-15 Besst Test Aps Test zum direkten nachweisen einer rs virus bezogenen biologischen zelle in einer körperflüssigkeitsprobe
US6315720B1 (en) 2000-10-23 2001-11-13 Celgene Corporation Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
US6485460B2 (en) 2001-01-12 2002-11-26 Bracco Diagnostics, Inc. Tamper evident syringe barrel
AU2002331408B2 (en) 2001-08-20 2008-05-08 Proteome Systems Ltd Diagnostic testing process and apparatus
WO2003016902A1 (fr) 2001-08-20 2003-02-27 Proteome Systems Intellectual Property Pty Ltd Procede et appareil d'epreuve diagnostique
US6605602B1 (en) 2001-09-28 2003-08-12 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Method of treating BK virus nephropathy
CA2478547C (fr) * 2001-12-03 2011-09-20 Abgenix, Inc. Identification de molecules de haute affinite par depistage par dilutions limitees
IL163725A0 (en) 2002-02-25 2005-12-18 Elan Pharm Inc Administration of agents for the treatment of inflammation
TW200307671A (en) 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
TWI281470B (en) 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
WO2004001539A2 (fr) 2002-06-21 2003-12-31 Mckesson Information Solutions Llc Systeme et procede de consommation de medicaments en boucle fermee
US20070275481A1 (en) 2003-11-24 2007-11-29 Biogen Idec Ma Inc. Methods For Detecting Half-Antibodies Using Chip Based Gel Electophoresis
JP4672263B2 (ja) 2004-01-27 2011-04-20 デンカ生研株式会社 簡便な検出法、検出装置及び検出キットとその製法
US7419666B1 (en) 2004-02-23 2008-09-02 Massachusetts Eye And Ear Infirmary Treatment of ocular disorders
TWI439284B (zh) 2004-04-09 2014-06-01 Abbvie Biotechnology Ltd 用於治療ＴＮＦα相關失調症之多重可變劑量療法
US20050283385A1 (en) 2004-06-21 2005-12-22 The Permanente Medical Group, Inc. Individualized healthcare management system
NZ588839A (en) 2004-07-08 2012-09-28 Elan Pharm Inc Multivalent vla-4 antagonists comprising polyethylene glycol moieties
CA2478458A1 (fr) 2004-08-20 2006-02-20 Michael Panzara Traitement de la sclerose en plaques pediatrique
EP1833509A4 (fr) 2004-12-03 2008-12-03 Biogen Idec Inc Retardement ou prevention de l'apparition d'une sclerose en plaques
EP1863940B1 (fr) 2005-03-03 2012-06-06 Seedlings Life Science Ventures, LLC. Méthode de gestion des risques concernant les patients soumis à un traitement à base de natalizumab
SI2645106T1 (en) 2005-04-04 2018-01-31 Biogen Ma Inc. METHODS FOR EVALUATION OF THE IMMUNE RESPONSE TO THERAPEUTIC MEDICINE
CA2614737A1 (fr) * 2005-07-08 2007-01-18 Philadelphia Health & Education Corporation D/B/A Drexel University Coll Ege Of Medicine Methodes permettant de controler la destruction des neurones par neuroinflammation et de traiter des maladies presentant une composante inflammatoire liee a la phospholipase a2
NZ567270A (en) 2005-09-29 2011-06-30 Elan Pharm Inc Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by VLA-4
EA017110B1 (ru) 2006-02-27 2012-09-28 Элан Фамэсьютикэлс, Инк. ПИРИМИДИНИЛСУЛЬФОНАМИДНЫЕ СОЕДИНЕНИЯ (ВАРИАНТЫ), СПОСОБ ПОЛУЧЕНИЯ ПИРИМИДИНИЛСУЛЬФОНАМИДНЫХ СОЕДИНЕНИЙ (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, ОПОСРЕДОВАННОГО ИНТЕГРИНОМ α4, СПОСОБ СНИЖЕНИЯ И/ИЛИ ПРЕДУПРЕЖДЕНИЯ ВОСПАЛИТЕЛЬНОГО КОМПОНЕНТА ЗАБОЛЕВАНИЯ ИЛИ АУТОИММУННОГО ОТВЕТА
LT2676967T (lt) 2006-02-28 2019-09-10 Biogen Ma Inc. Uždegiminių ir autoimuninių ligų gydymo būdai su natalizumabu
US8410115B2 (en) 2006-02-28 2013-04-02 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
ES2663377T3 (es) 2006-03-03 2018-04-12 Biogen Ma Inc. Métodos para el tratamiento de enfermedades inflamatorias y autoinmunes con natalizumab
WO2008021954A2 (fr) * 2006-08-09 2008-02-21 Biogen Idec Ma Inc. Procédé de distribution d'un médicament
TWI415845B (zh) * 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物
US20080233150A1 (en) 2006-11-16 2008-09-25 Gale Smith Respiratory syncytial virus-virus like particle (vlps)
EP1933140B1 (fr) 2006-12-11 2011-08-17 AraGen Biotechnology Co. Ltd. Procédé pour la détection des anticorps par un signal d'or colloïdal amplifié par des oligonucléotides
TW200846363A (en) * 2007-03-22 2008-12-01 Urrma R & B Novel human anti-R7V antibodies and uses thereof
FR2919804B1 (fr) * 2007-08-08 2010-08-27 Erytech Pharma Composition et vaccin therapeutique anti-tumoral
EP4335932A3 (fr) * 2008-11-07 2024-06-26 Adaptive Biotechnologies Corporation Procédés de surveillance de conditions par analyse de séquence
EP2394163B1 (fr) 2009-02-05 2020-08-19 Biogen MA Inc. Procédés pour détecter le polyomavirus jc
WO2010096674A2 (fr) 2009-02-20 2010-08-26 The Regents Of The University Of California Dosages de biomarqueur a+
HUE043339T2 (hu) 2011-05-31 2019-08-28 Biogen Ma Inc Módszer a PML kockázatának megállapítására
WO2014193804A1 (fr) * 2013-05-28 2014-12-04 Biogen Idec Ma Inc. Méthodes d'évaluation de risque de développement d'une lemp

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011085369A1 (fr) * 2010-01-11 2011-07-14 Biogen Idec Ma Inc. Essai d'anticorps anti-virus jc

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
LEONID GORELIK ET AL: "Anti-JC virus antibodies: Implications for PML Risk Stratification", ANNALS OF NEUROLOGY, vol. 68, no. 3, 24 August 2010 (2010-08-24), pages 295 - 303, XP055136721, ISSN: 0364-5134, DOI: 10.1002/ana.22128 *
PLAVINA T ET AL: "Anti-JCV antibody index further defines PML risk in natalizumab-treated MS patients The 27th Annual Meeting of the Consortium of Multiple Sclerosis Centers ACKNOWLEDGMENTS", ACCESSED MARCH NEUROLOGY. NEUROLOGY. WARNKE C J NEUROL NEUROSURG PSYCHIATRY ANN NEUROL, 30 May 2013 (2013-05-30), pages 1736 - 1742742, XP055190187, Retrieved from the Internet <URL:https://cmscactrims.confex.com/cmscactrims/2013/webprogram/Handout/Paper1642/Plavina_Tysabri JCV Ab Index_2013 CMSC Poster_FINAL.pdf> [retrieved on 20150519] *
SANDROCK ALFRED ET AL: "Risk Stratification for Progressive Multifocal Leukoencephalopathy (PML) in MS Patients: Role of Prior Immunosuppressant Use, Natalizumab-Treatment Duration, and Anti-JCV Antibody Status", NEUROLOGY, vol. 76, no. 9, Suppl. 4, March 2011 (2011-03-01), & 63RD ANNUAL MEETING OF THE AMERICAN-ACADEMY-OF-NEUROLOGY; HONOLULU, HI, USA; APRIL 09 -16, 2011, pages A248, XP055189963, ISSN: 0028-3878 *
SUBRAMANYAM MEENA ET AL: "Anti-JCV Antibodies Are Consistently Detected Prior to and after PML Diagnosis in Natalizumab-Treated MS Patients", NEUROLOGY, vol. 76, no. 9, Suppl. 4, March 2011 (2011-03-01), & 63RD ANNUAL MEETING OF THE AMERICAN-ACADEMY-OF-NEUROLOGY; HONOLULU, HI, USA; APRIL 09 -16, 2011, pages A636 - A637, XP008176353, ISSN: 0028-3878 *
WARNKE CLEMENS ET AL: "Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?", ARCHIVES OF NEUROLOGY,, vol. 67, no. 8, 1 August 2010 (2010-08-01), pages 923 - 930, XP009146630, DOI: 10.1001/ARCHNEUROL.2010.161 *

Also Published As

Publication number Publication date
FI3575792T3 (fi) 2023-03-17
CN103635803A (zh) 2014-03-12
US20220011310A1 (en) 2022-01-13
HRP20190860T1 (hr) 2019-06-28
WO2012166971A8 (fr) 2013-01-17
JP7128221B2 (ja) 2022-08-30
US12066442B2 (en) 2024-08-20
JP2023169307A (ja) 2023-11-29
EP2715352A2 (fr) 2014-04-09
CA2836490A1 (fr) 2012-12-06
KR20140038440A (ko) 2014-03-28
JP2020101556A (ja) 2020-07-02
JP7353338B2 (ja) 2023-09-29
JP2022023126A (ja) 2022-02-07
KR20190122878A (ko) 2019-10-30
HUE043339T2 (hu) 2019-08-28
US20190227064A1 (en) 2019-07-25
RS58967B1 (sr) 2019-08-30
US12105090B2 (en) 2024-10-01
KR102292563B1 (ko) 2021-08-24
ES2729945T3 (es) 2019-11-07
PT2715352T (pt) 2019-06-12
EP4187248A1 (fr) 2023-05-31
KR102039751B1 (ko) 2019-11-01
EP3575792B1 (fr) 2022-11-30
CY1121981T1 (el) 2020-10-14
KR102473834B1 (ko) 2022-12-02
JP6663396B2 (ja) 2020-03-11
WO2012166971A2 (fr) 2012-12-06
LT3575792T (lt) 2023-03-10
AU2012262122B2 (en) 2016-12-08
AU2012262122A1 (en) 2013-11-14
RS63989B1 (sr) 2023-03-31
PL2715352T3 (pl) 2019-09-30
EP2715352B1 (fr) 2019-04-24
HRP20230186T1 (hr) 2023-03-31
JP6243838B2 (ja) 2017-12-06
KR20210107138A (ko) 2021-08-31
JP2017191111A (ja) 2017-10-19
PT3575792T (pt) 2023-02-28
PL3575792T3 (pl) 2023-03-27
WO2012166971A3 (fr) 2013-03-07
LT2715352T (lt) 2019-06-10
JP2014518377A (ja) 2014-07-28
SI2715352T1 (sl) 2019-06-28
DK3575792T3 (da) 2023-02-27
SI3575792T1 (sl) 2023-04-28
ES2939482T3 (es) 2023-04-24
EP3575792A1 (fr) 2019-12-04
HUE061244T2 (hu) 2023-06-28
DK2715352T3 (da) 2019-05-20

Similar Documents

Publication Publication Date Title
PT2715352T (pt) Método de avaliação do risco de lmp
GB201113087D0 (en) Method
EP2716970A4 (fr) Procédé de fusion de déchets
GB201116530D0 (en) Method
GB201105436D0 (en) Method
GB201112447D0 (en) Method
GB201114919D0 (en) Method
GB201114325D0 (en) Method
GB201101219D0 (en) Method
GB201322533D0 (en) Assessment method
GB201111189D0 (en) Method
GB201215942D0 (en) Method of treatent
GB201117358D0 (en) Method
GB201115783D0 (en) Method
GB201111673D0 (en) Method
GB201108041D0 (en) Method
ZA201401630B (en) Method for assessing perspiration reduction
GB201220282D0 (en) Electrochemical method
GB201114391D0 (en) Method
GB201106283D0 (en) Method
GB201212279D0 (en) Method of construction
EP2756910A4 (fr) Procédé de liaison métallique
PL397508A1 (pl) Sposób otrzymywania stopów ren-nikiel
GB201115112D0 (en) Method
GB201114347D0 (en) Method

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20131119

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1196155

Country of ref document: HK

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/569 20060101AFI20150526BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIOGEN MA INC.

A4 Supplementary search report drawn up and despatched

Effective date: 20150918

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/569 20060101AFI20150914BHEP

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

R17P Request for examination filed (corrected)

Effective date: 20131119

17Q First examination report despatched

Effective date: 20160531

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20180828

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIOGEN MA INC.

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

GRAL Information related to payment of fee for publishing/printing deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR3

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTC Intention to grant announced (deleted)
INTG Intention to grant announced

Effective date: 20190129

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20190860

Country of ref document: HR

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1124743

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190515

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602012059385

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20190516

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 2715352

Country of ref document: PT

Date of ref document: 20190612

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20190530

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20190860

Country of ref document: HR

Ref country code: CH

Ref legal event code: NV

Representative=s name: STOLMAR AND PARTNER INTELLECTUAL PROPERTY S.A., CH

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20190424

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20190860

Country of ref document: HR

Payment date: 20190724

Year of fee payment: 8

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E017675

Country of ref document: EE

Effective date: 20190604

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E043339

Country of ref document: HU

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 31117

Country of ref document: SK

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20190401648

Country of ref document: GR

Effective date: 20190906

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2729945

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20191107

REG Reference to a national code

Ref country code: DE

Ref legal event code: R026

Ref document number: 602012059385

Country of ref document: DE

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

REG Reference to a national code

Ref country code: FI

Ref legal event code: MDE

Opponent name: POLPHARMA BIOLOGICS S.A.

26 Opposition filed

Opponent name: POLPHARMA BIOLOGICS S.A.

Effective date: 20200117

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20190860

Country of ref document: HR

Payment date: 20200408

Year of fee payment: 9

PLBB Reply of patent proprietor to notice(s) of opposition received

Free format text: ORIGINAL CODE: EPIDOSNOBS3

REG Reference to a national code

Ref country code: HU

Ref legal event code: HC9C

Owner name: BIOGEN MA INC., US

RDAF Communication despatched that patent is revoked

Free format text: ORIGINAL CODE: EPIDOSNREV1

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20190860

Country of ref document: HR

Payment date: 20210528

Year of fee payment: 10

APBM Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNO

APBP Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2O

APAH Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNO

APBQ Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3O

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BG

Payment date: 20220309

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LV

Payment date: 20220321

Year of fee payment: 11

Ref country code: PL

Payment date: 20220323

Year of fee payment: 11

Ref country code: MK

Payment date: 20220328

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20220420

Year of fee payment: 11

APAH Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNO

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20190860

Country of ref document: HR

Payment date: 20220527

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SM

Payment date: 20220429

Year of fee payment: 11

Ref country code: SK

Payment date: 20220413

Year of fee payment: 11

Ref country code: SE

Payment date: 20220411

Year of fee payment: 11

Ref country code: RS

Payment date: 20220418

Year of fee payment: 11

Ref country code: RO

Payment date: 20220427

Year of fee payment: 11

Ref country code: PT

Payment date: 20220531

Year of fee payment: 11

Ref country code: NO

Payment date: 20220510

Year of fee payment: 11

Ref country code: MC

Payment date: 20220426

Year of fee payment: 11

Ref country code: LU

Payment date: 20220512

Year of fee payment: 11

Ref country code: LT

Payment date: 20220427

Year of fee payment: 11

Ref country code: IT

Payment date: 20220412

Year of fee payment: 11

Ref country code: IE

Payment date: 20220413

Year of fee payment: 11

Ref country code: HU

Payment date: 20220412

Year of fee payment: 11

Ref country code: HR

Payment date: 20220527

Year of fee payment: 11

Ref country code: GB

Payment date: 20220407

Year of fee payment: 11

Ref country code: FR

Payment date: 20220408

Year of fee payment: 11

Ref country code: ES

Payment date: 20220603

Year of fee payment: 11

Ref country code: EE

Payment date: 20220421

Year of fee payment: 11

Ref country code: DK

Payment date: 20220510

Year of fee payment: 11

Ref country code: DE

Payment date: 20220406

Year of fee payment: 11

Ref country code: CZ

Payment date: 20220517

Year of fee payment: 11

Ref country code: CY

Payment date: 20220406

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20220531

Year of fee payment: 11

Ref country code: SI

Payment date: 20220401

Year of fee payment: 11

Ref country code: GR

Payment date: 20220420

Year of fee payment: 11

Ref country code: FI

Payment date: 20220509

Year of fee payment: 11

Ref country code: CH

Payment date: 20220421

Year of fee payment: 11

Ref country code: BE

Payment date: 20220420

Year of fee payment: 11

Ref country code: AT

Payment date: 20220425

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MT

Payment date: 20220526

Year of fee payment: 11

Ref country code: IS

Payment date: 20220405

Year of fee payment: 11

REG Reference to a national code

Ref country code: HU

Ref legal event code: HC9C

Owner name: BIOGEN MA INC., US

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AL

Payment date: 20220517

Year of fee payment: 11

REG Reference to a national code

Ref country code: DE

Ref legal event code: R103

Ref document number: 602012059385

Country of ref document: DE

Ref country code: DE

Ref legal event code: R064

Ref document number: 602012059385

Country of ref document: DE

APBU Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9O

RDAG Patent revoked

Free format text: ORIGINAL CODE: 0009271

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: PATENT REVOKED

REG Reference to a national code

Ref country code: LT

Ref legal event code: MM9A

Effective date: 20320531

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

27W Patent revoked

Effective date: 20230209

GBPR Gb: patent revoked under art. 102 of the ep convention designating the uk as contracting state

Effective date: 20230209

REG Reference to a national code

Ref country code: SK

Ref legal event code: MC4A

Ref document number: E 31117

Country of ref document: SK

Effective date: 20230209

REG Reference to a national code

Ref country code: GR

Ref legal event code: NF

Ref document number: 20190401648

Country of ref document: GR

Effective date: 20230410

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 1124743

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190424

Ref country code: EE

Ref legal event code: MF4A

Ref document number: E017675

Country of ref document: EE

Effective date: 20230321

REG Reference to a national code

Ref country code: AT

Ref legal event code: MA03

Ref document number: 1124743

Country of ref document: AT

Kind code of ref document: T

Effective date: 20230209

REG Reference to a national code

Ref country code: HR

Ref legal event code: PNEV

Ref document number: P20190860

Country of ref document: HR

REG Reference to a national code

Ref country code: SE

Ref legal event code: ECNC

REG Reference to a national code

Ref country code: SI

Ref legal event code: NC00

Effective date: 20231120